Effector Therapeutics Stock Price To Earnings To Growth
EFTRWDelisted Stock | USD 0 0.00 0.00% |
EFFECTOR Therapeutics fundamentals help investors to digest information that contributes to EFFECTOR Therapeutics' financial success or failures. It also enables traders to predict the movement of EFFECTOR Pink Sheet. The fundamental analysis module provides a way to measure EFFECTOR Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to EFFECTOR Therapeutics pink sheet.
EFFECTOR |
EFFECTOR Therapeutics Company Price To Earnings To Growth Analysis
EFFECTOR Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
CompetitionBased on the latest financial disclosure, EFFECTOR Therapeutics has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Bonds Directory Now
Bonds DirectoryFind actively traded corporate debentures issued by US companies |
All Next | Launch Module |
EFFECTOR Fundamentals
Return On Equity | -9.47 | |||
Return On Asset | -0.83 | |||
Number Of Shares Shorted | 18.44 K | |||
EBITDA | (33.73 M) | |||
Net Income | (35.81 M) | |||
Total Debt | 19.45 M | |||
Book Value Per Share | 0.21 X | |||
Cash Flow From Operations | (29.55 M) | |||
Earnings Per Share | (0.91) X | |||
Number Of Employees | 14 | |||
Beta | 0.62 | |||
Total Asset | 20.54 M | |||
Retained Earnings | (179.38 M) | |||
Working Capital | (5.96 M) | |||
Net Asset | 20.54 M |
About EFFECTOR Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze EFFECTOR Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of EFFECTOR Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of EFFECTOR Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in EFFECTOR Pink Sheet
If you are still planning to invest in EFFECTOR Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the EFFECTOR Therapeutics' history and understand the potential risks before investing.
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
CEOs Directory Screen CEOs from public companies around the world | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |